Development and validation of a computational tool to predict treatment outcomes in cells from high-grade serous ovarian cancer patients
Related Experiment Video
Updated: Jan 11, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Marilisa Cortesi1,2, Dongli Liu2, Elyse Powell2
1Department of Electrical Electronic and Information Engineering "G.Marconi" University of Bologna Cesena Italy.
Abstract:
Treatment of High-grade serous ovarian cancer (HGSOC) is often ineffective due to frequent late-stage diagnosis and development of resistance to therapy. Timely selection of the most effective (combination of) drug(s) for each patient would improve outcomes, however the tools currently available to clinicians are poorly suited to the task. We here present a computational simulator capable of recapitulating cell response to treatment in ovarian cancer. The technical development of the in silico framework is described, together with its validation on both cell lines and patient- derived laboratory models. A calibration procedure to identify the parameters that best recapitulate each patient's response is also presented. Our results support the use of this tool in preclinical research, to provide relevant insights into HGSOC behavior and progression. They also provide a proof of concept for its use as a personalized medicine tool and support disease monitoring and treatment selection.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020